Ryan Trowbridge, MD
Dermatology · Omaha, NENPI 1770996191
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 391 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,125, more than ten times the $163 reported in 2020.
Across 391 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$853
- Lilly USA, LLC$683
- Sun Pharmaceutical Industries Inc.$599
- Pfizer$457
- Amgen$434
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,98692%
- Education$5518%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 60 | $1,252 |
| AbbVie | 50 | $853 |
| Lilly USA, LLC | 53 | $683 |
| Sun Pharmaceutical Industries Inc. | 27 | $599 |
| Pfizer | 56 | $457 |
| Amgen | 24 | $434 |
| Novartis | 21 | $358 |
| UCB, Inc. | 16 | $322 |
| Incyte Corporation | 13 | $264 |
| E.r. Squibb & Sons, L.L.C. | 8 | $149 |
| Regeneron Healthcare Solutions, Inc. | 5 | $111 |
| Sanofi | 7 | $110 |
| Novo Nordisk | 6 | $100 |
| Sandoz | 5 | $99 |
| Hologic Sales And Service, LLC | 1 | $96 |
| ANI Pharmaceuticals, Inc. | 5 | $78 |
| Dermavant Sciences, Inc. | 4 | $73 |
| LEO Pharma Inc. | 4 | $58 |
| Organon | 5 | $56 |
| Galderma Laboratories, L.p. | 3 | $50 |
| Aurinia Pharma U.S., Inc. | 3 | $44 |
| Boehringer Ingelheim | 2 | $39 |
| Botanix SB Inc | 2 | $32 |
| Esperion Therapeutics, Inc. | 1 | $29 |
| Kyowa Kirin, Inc. | 2 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $28 |
| Genentech USA, Inc. | 1 | $27 |
| Krystal Biotech Inc | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| GSK | 1 | $19 |
| Arcutis Biotherapeutics, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$6,537 in reported general payments places this provider in the 70th percentile of 68 dermatology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 12 | $267,307 |
| Cosentyx Unoready PenSecukinumab | 14 | $146,200 |
| Dupixent PenDupilumab | 29 | $123,880 |
| XeljanzTofacitinib Citrate | 16 | $107,401 |
| Clobetasol Propionate | 51 | $2,267 |
| Fluorouracil | 19 | $1,574 |
| Tacrolimus | 22 | $1,459 |
| Triamcinolone Acetonide | 76 | $982 |
| Mycophenolate Mofetil | 20 | $961 |
| Doxycycline Hyclate | 28 | $927 |
| Metronidazole | 16 | $806 |
| Glycopyrrolate | 14 | $683 |
| Hydroxychloroquine Sulfate | 27 | $663 |
| MethotrexateMethotrexate Sodium | 40 | $579 |
| Ketoconazole | 30 | $559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerXeljanz | $457 | $107,40116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 68 dermatology providers in Nebraska.
Other dermatology in Omaha
- Rachel PersonOmaha$98K
- Erin BarrettOmaha$96K
- Joel SchlessingerOmaha$89K
- Mathew DaveyOmaha$35K
- Gage RenschOmaha$11K
- Herschel StollerOmaha$10K
- Deirdre StolmeierOmaha$10K
- Melissa DarlingOmaha$10K
- Christopher HuerterOmaha$7K
- Tina KinsleyOmaha$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.